<DOC>
	<DOCNO>NCT01240655</DOCNO>
	<brief_summary>This dose escalation study assess safety efficacy LCL161 combination weekly paclitaxel adult patient advance solid tumor .</brief_summary>
	<brief_title>A Study LCL161 Combination With Weekly Paclitaxel Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients breast cancer must histologically cytologically confirm diagnosis disease metastasize resistant therapy . Patients ovarian cancer must histological evidence recurrent epithelial ovarian , fallopian tube peritoneal cancer . Patients must recover stabilized toxicity relate previous treatment except alopecia Male female patient 18 year old ECOG performance status 01 Life expectancy great 12 week Measurable disease determine RECIST v1.0 Patients must give write informed consent comply protocol For patient breast cancer : Concurrent Her2directed antiestrogen therapy For patient ovarian cancer : Primary refractory disease , define progression initial treatment platinum taxanecontaining regimen . Prior treatment weekly paclitaxel . More two chemotherapy regimen give relapse set . Evidence document bowel obstruction within six month study entry Patients unresolved peripheral neuropathy , nausea , vomit , diarrhea ≥ CTCAE Grade 2 Any concurrent severe and/or uncontrolled medical condition could increase patient 's risk toxicity study could confound discrimination disease study treatmentrelated toxicity . Patients impairment GI function GI disease may significantly alter absorption LCL161 Patients undergone major surgery ≤ 3 week prior start study drug recover side effect procedure . Pregnant breast feeding ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive βHCG laboratory test ( &gt; 5 mIU/mL ) . Known diagnosis human immunodeficiency virus ( HIV ) infection chronic active hepatitis B C ( HIV hepatitis test mandatory ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>LCL161</keyword>
	<keyword>solid tumor</keyword>
	<keyword>paclitaxel</keyword>
</DOC>